NLS Pharmaceutics AG (NLSP)

NLS Pharmaceutics AG Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	0.9	8.95	5.43	0.09	0.22
Cash & Cash Equivalents	0.9	8.95	5.43	0.09	0.22
Cash Growth	-89.97%	64.76%	5695.69%	-57.46%	3198.40%
Other Current Assets	0.93	0.3	0.29	0.1	0.16
Total Current Assets	1.82	9.25	5.72	0.2	0.38
Property, Plant & Equipment	0.01	0.02	0.03	0	0
Other Long-Term Assets	0.02	0.01	0.01	1.01	0.31
Total Long-Term Assets	0.02	0.03	0.04	1.01	0.31
Total Assets	1.85	9.28	5.76	1.21	0.7
Accounts Payable	4.63	2.37	1.74	4.01	2.51
Deferred Revenue	2.5	2.5	2.5	2.5	2.5
Current Debt	1.63	0	0	1.77	0.69
Other Current Liabilities	-0.85	-1.51	-1.83	-1.07	-1.66
Total Current Liabilities	7.92	3.36	2.4	7.2	4.04
Long-Term Debt	0	0	0	0.31	0.15
Other Long-Term Liabilities	2.76	2.64	2.82	2.68	2.68
Total Long-Term Liabilities	2.76	2.64	2.82	2.99	2.83
Total Liabilities	10.68	6	5.22	10.2	6.87
Total Debt	1.63	0	0	2.08	0.84
Debt Growth	-	-	-	147.56%	-88.13%
Retained Earnings	-70.37	-58.2	-41.71	-29.76	-26.9
Comprehensive Income	-0.16	-0.05	-0.15	-0.02	-0.02
Shareholders' Equity	-8.83	3.28	0.54	-8.98	-6.17
Net Cash / Debt	-0.74	8.95	5.43	-1.99	-0.62
Net Cash / Debt Growth	-	64.76%	-	-	-
Net Cash Per Share	-0.02	0.45	0.46	-0.29	-0.09
Working Capital	-6.1	5.89	3.32	-7.01	-3.65
Book Value Per Share	-0.23	0.17	0.05	-1.29	-0.90

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).